ClinicalTrials.gg
CompletedNCT01451398Updated Oct 17, 2014Results posted

Comparison of Technosphere® Insulin Versus Technosphere Powder (Placebo) in Insulin-Naive Subjects With Type 2 Diabetes Mellitus

A Phase 3 interventional study of Technosphere® Insulin and Technosphere Powder in Type 2 Diabetes, sponsored by Mannkind Corporation. Completed at 76 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-17.

Sponsored by Mannkind Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
353
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 — none open to participants now, 1 under way, none of them phase 3. Insulin, Regular, Human · Diabetes Mellitus, Type 2.

Enrollment
14th of 49
353 · median 129
Started
2011
with 2 others
Phase 3
25 of 49
none open now
Registered
35th of 49
by date
Lead sponsor
13 of 49
Mannkind Corporation

Among the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2, this one is the 14th largest by enrollment, is one of 3 that started in 2011, is one of 25 in phase 3, and was the 35th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About Insulin, Regular, Human

Insulin, Regular, Human: first FDA approval 1982 (HUMULIN R PEN), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 49 studies testing Insulin, Regular, Human in Diabetes Mellitus, Type 2 as a file.
02

Study summary

Insulin-naive subjects with Type 2 Diabetes Mellitus who are sub-optimally controlled on either maximum tolerated dose of metformin or maximum tolerated dose of metformin plus one or two other oral anti-diabetic medications will have either Prandial Technosphere® Insulin or Technosphere Powder (placebo) added to their oral antidiabetic drugs.

03

Conditions studied

  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • > or = to 7.5% and \< or = to 10.0%
  • (BMI) \< or = to 45 kg/m2
  • Non smoker for at least 6 months before Screening
  • Clinical diagnosis of type 2 diabetes mellitus for more than 12 months
  • Currently receiving as diabetes treatment only metformin or 2 or more OADs and on stable doses for at least 3 months before enrollment

    • Subjects receiving metformin must be on at least 1.5gm daily, or up to the maximum tolerated dose
    • Subjects treated with a sulfonylurea must be on at least 50% of the total maximum approved dose for a given agent
    • Subjects receiving a DPP-4 inhibitor must receive the maximum approved dose specific for that agent
    • Metiglinide and alpha-glucoside inhibitors must be taken at the highest tolerated dose within the approved dose range
  • No previous or current treatment with insulin, except during an acute illness, gestational diabetes, or at time of initial diagnosis of diabetes
  • (FEV1) > or = to 70% Third National Health and Nutrition Examination Survey (NHANES III) predicted
  • Forced vital capacity (FVC) > or = to 70% NHANES III predicted
  • Forced expiratory volume in one second as a percentage of forced vital capacity (FEV1/FVC) > or = to NHANES III lower limit of normal (LLN)

Exclusion criteria

Exclusion Criteria:

  • History of (COPD), clinically proven asthma, or any other pulmonary disease (eg, pulmonary fibrosis)
  • Any clinically significant radiological findings on screening chest x-ray
  • Use of medications for asthma, COPD, or any other chronic respiratory conditions
  • Evidence of serious complications of diabetes (proliferative retinopathy, autonomic neuropathy with symptoms of gastroparesis or cardiac arrhythmia; sensory neuropathy that makes manipulation of the Gen2C inhaler difficult)
  • Renal disease or renal dysfunction
  • Significant cardiovascular dysfunction or history thereof within 12 months of screening; serious arrhythmia, treatment with medications to control/treat arrhythmias; myocardial infarction; cardiac surgery; history of valvular heart disease
  • Previous or current use of amiodarone
  • Treatment with glucagon-like peptide-1 (GLP-1) analogs, thiazolidinediones (TZD), or weight loss drugs (eg, sibutramine, orlistat) within 3 months of screening
  • History of pulmonary embolism or deep venous thrombosis in the 12 months before Screening
  • History of recent blood transfusion (within previous 3 months) or diagnosis of hemoglobinopathies that may affect measurements
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
353 participants (actual)

Study arms

  • Experimental
    TI inhalation powder

    Technosphere® Insulin powder administered via the Gen2 inhaler added to 2 or more stable OADs

    Drug: Technosphere® Insulin

  • Placebo comparator
    Technosphere powder

    Technosphere powder (with no insulin) administered via the Gen2 inhaler added to 2 or more stable OADs

    Drug: Technosphere Powder

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 24 in HbA1c

    Efficacy as measured by change in glycated hemoglobin (HbA1c) at Week 24

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Proportion of Responders Achieving HbA1c <= 7.0%

    Efficacy as measured in proportion of subjects achieving HbA1c \< or = to 7.0%

    Time frame: Week 24

  2. Proportion of Responders Achieving HbA1c <= 6.5%

    Efficacy as measured in proportion of subjects achieving HbA1c \< or = to 6.5% at Week 24

    Time frame: Week 24

  3. FPG Change From Baseline to Week 24

    Efficacy as measured by mean change in fasting plasma glucose (FPG)

    Time frame: Baseline to Week 24

  4. Proportion of Subjects Requiring Rescue Therapy

    Time frame: Baseline to Week 24

  5. Time to Rescue

    Time from Week 0 (baseline) to initiation of rescue therapy (up to a maximum of 24 weeks/end of treatment) for subjects not responding to treatment

    Time frame: Baseline to Week 24

  6. FEV1 Change From Baseline to Week 24

    Forced Expiratory Volume in 1 second - change from baseline to week 24

    Time frame: Baseline to Week 24

  7. Incidence of Total Hypoglycemia

    Hypoglycemia, defined as blood glucose \<= 70 mg/dL or in absence of blood glucose, symptoms that are resolved by the administration of carbohydrates.

    Time frame: Baseline to Week 24

  8. Incidence of Severe Hypoglycemia

    Severe Hypoglycemia defined as: Requiring 3rd party assistance.

    Time frame: Baseline to Week 24

  9. Total Hypoglycemia Event Rate

    Number of Hypoglycemic Events/Total Subject Exposure Time (in months)

    Time frame: Baseline to Week 24

  10. Severe Hypoglycemia Event Rate

    Number of Severe Hypoglycemic Events/Total Subject Exposure Time (in months)

    Time frame: Baseline to Week 24

  11. Mean 7-point Glucose Baseline Values

    Mean 7-point self-monitored glucose at baseline

    Time frame: Baseline

  12. Mean 7-point Glucose Week 24 Values

    Mean 7-point self-monitored blood glucose at Week 24

    Time frame: Week 24

  13. Change in Body Weight From Baseline to Week 24

    Change in body weight from Baseline to Week 24

    Time frame: Baseline to Week 24

07

Results

Posted Oct 17, 2014

Participant flow

First Patient enrolled November 2011. Multi-national trial conducted in US, Russia, Ukraine and Brazil

Participant flow — Overall Study
MilestoneTI Inhalation Powder + OADsTechnosphere Powder
Started177176
Completed150139
Not completed2737
Withdrew: Adverse event79
Withdrew: Protocol violation12
Withdrew: Physician decision11
Withdrew: Withdrawal by subject1014
Withdrew: Lost to follow-up64
Withdrew: Non-compliance with study drug13
Withdrew: Non-compliance with protocol11
Withdrew: Moved out of country01
Withdrew: Adverse event + elevated fasting glucose01
Withdrew: Lack of efficacy01

Outcome measures

PrimaryChange From Baseline to Week 24 in HbA1c

Efficacy as measured by change in glycated hemoglobin (HbA1c) at Week 24

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · percentage of hemoglobin
Change From Baseline to Week 24 in HbA1c
percentage of hemoglobinTI Inhalation Powder + OADsTechnosphere Powder
Change From Baseline to Week 24 in HbA1c-0.82 ± 0.061-0.42 ± 0.062
Statistical analysis
  • TI Inhalation Powder + OADs vs Technosphere Powder · Mixed Models Analysis · p = <0.0001 · Mean difference (final values): -0.40 · 95% CI -0.57 to -0.23Change in HbA1c = Baseline HbA1c + Region + Pooled OAD Strata + Visit + Treatment + (Treatment\*Visit), using AR(1) variance/covariance structure.
SecondaryProportion of Responders Achieving HbA1c <= 7.0%

Efficacy as measured in proportion of subjects achieving HbA1c \< or = to 7.0%

Time frame:
Week 24
Reported as:
Number · percentage of participants
Proportion of Responders Achieving HbA1c <= 7.0%
percentage of participantsTI Inhalation Powder + OADsTechnosphere Powder
Proportion of Responders Achieving HbA1c <= 7.0%37.719.0
Statistical analysis
  • TI Inhalation Powder + OADs vs Technosphere Powder · Regression, Logistic · p = 0.0005 · Odds ratio (or): 2.726 · 95% CI 1.55 to 4.80Model: Treatment + Pooled OAD Stratum + Region + Baseline HbA1c
SecondaryProportion of Responders Achieving HbA1c <= 6.5%

Efficacy as measured in proportion of subjects achieving HbA1c \< or = to 6.5% at Week 24

Time frame:
Week 24
Reported as:
Number · percentage of participants
Proportion of Responders Achieving HbA1c <= 6.5%
percentage of participantsTI Inhalation Powder + OADsTechnosphere Powder
Proportion of Responders Achieving HbA1c <= 6.5%15.94.2
Statistical analysis
  • TI Inhalation Powder + OADs vs Technosphere Powder · Regression, Logistic · p = 0.0021 · Odds ratio (or): 4.361 · 95% CI 1.70 to 11.17Model: Treatment + Pooled OAD Stratum + Region + Baseline HbA1c
SecondaryFPG Change From Baseline to Week 24

Efficacy as measured by mean change in fasting plasma glucose (FPG)

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · mg/dL
FPG Change From Baseline to Week 24
mg/dLTI Inhalation Powder + OADsTechnosphere Powder
FPG Change From Baseline to Week 24-11.20 ± 3.776-3.78 ± 3.864
Statistical analysis
  • TI Inhalation Powder + OADs vs Technosphere Powder · Mixed Models Analysis · p = 0.1698 · Mean difference (net): -7.42 · 95% CI -18.03 to 3.18Model: FPG = Baseline FPG + Region + Pooled OAD Stratum + Visit + Treatment + (Treatment \* Visit) Variance/Covariance Matrix is Autoregression 1
SecondaryProportion of Subjects Requiring Rescue Therapy
Time frame:
Baseline to Week 24
Reported as:
Number · percentage of participants
Proportion of Subjects Requiring Rescue Therapy
percentage of participantsTI Inhalation Powder + OADsTechnosphere Powder
Proportion of Subjects Requiring Rescue Therapy6.89.7
SecondaryTime to Rescue

Time from Week 0 (baseline) to initiation of rescue therapy (up to a maximum of 24 weeks/end of treatment) for subjects not responding to treatment

Time frame:
Baseline to Week 24
Reported as:
Median · Days
Time to Rescue
DaysTI Inhalation Powder + OADsTechnosphere Powder
Time to Rescue95 (22 to 141)85 (28 to 160)
SecondaryFEV1 Change From Baseline to Week 24

Forced Expiratory Volume in 1 second - change from baseline to week 24

Time frame:
Baseline to Week 24
Reported as:
Mean · Liters
FEV1 Change From Baseline to Week 24
LitersTI Inhalation Powder + OADsTechnosphere Powder
FEV1 Change From Baseline to Week 24-0.13 ± 0.175-0.04 ± 0.147
Statistical analysis
  • TI Inhalation Powder + OADs vs Technosphere Powder · Mixed Models Analysis · Mean difference (final values): -0.09 · 95% CI -0.12 to -0.05FEV1 = Baseline FEV1 + Age + Gender + Race + Height + Visit + Treatment + (Treatment\*Visit)
SecondaryIncidence of Total Hypoglycemia

Hypoglycemia, defined as blood glucose \<= 70 mg/dL or in absence of blood glucose, symptoms that are resolved by the administration of carbohydrates.

Time frame:
Baseline to Week 24
Reported as:
Number · percentage of participants
Incidence of Total Hypoglycemia
percentage of participantsTI Inhalation Powder + OADsTechnosphere Powder
Incidence of Total Hypoglycemia67.830.7
SecondaryIncidence of Severe Hypoglycemia

Severe Hypoglycemia defined as: Requiring 3rd party assistance.

Time frame:
Baseline to Week 24
Reported as:
Number · percentage of participants
Incidence of Severe Hypoglycemia
percentage of participantsTI Inhalation Powder + OADsTechnosphere Powder
Incidence of Severe Hypoglycemia5.11.7
SecondaryTotal Hypoglycemia Event Rate

Number of Hypoglycemic Events/Total Subject Exposure Time (in months)

Time frame:
Baseline to Week 24
Reported as:
Number · Events/Subject-Month
Total Hypoglycemia Event Rate
Events/Subject-MonthTI Inhalation Powder + OADsTechnosphere Powder
Total Hypoglycemia Event Rate1.160.50
Statistical analysis
  • TI Inhalation Powder + OADs vs Technosphere Powder · Negative binomial regression · p = <0.0001Model: Treatment + Region + OAD Stratum + Exposure Time
SecondarySevere Hypoglycemia Event Rate

Number of Severe Hypoglycemic Events/Total Subject Exposure Time (in months)

Time frame:
Baseline to Week 24
Reported as:
Number · Events/100 Subject-Month
Severe Hypoglycemia Event Rate
Events/100 Subject-MonthTI Inhalation Powder + OADsTechnosphere Powder
Severe Hypoglycemia Event Rate2.370.60
Statistical analysis
  • TI Inhalation Powder + OADs vs Technosphere Powder · Negative Binomial Regression · p = 0.2024Model: Treatment + Region + OAD Stratum + Exposure Time
SecondaryMean 7-point Glucose Baseline Values

Mean 7-point self-monitored glucose at baseline

Time frame:
Baseline
Reported as:
Mean · mg/dL
Mean 7-point Glucose Baseline Values
mg/dLTI Inhalation Powder + OADsTechnosphere Powder
Before Breakfast178.5 ± 37.58182.2 ± 40.50
After Breakfast212.8 ± 51.01219.9 ± 51.77
Before Lunch176.7 ± 49.58183.6 ± 53.76
After Lunch197.0 ± 46.94209.1 ± 44.37
Before Dinner176.8 ± 41.81187.6 ± 50.04
After Dinner205.2 ± 48.72211.2 ± 50.44
Bedtime203.3 ± 50.55203.8 ± 46.52
SecondaryMean 7-point Glucose Week 24 Values

Mean 7-point self-monitored blood glucose at Week 24

Time frame:
Week 24
Reported as:
Mean · mg/dL
Mean 7-point Glucose Week 24 Values
mg/dLTI Inhalation Powder + OADsTechnosphere Powder
Before Breakfast156.6 ± 30.80160.9 ± 36.7
After Breakfast170.3 ± 44.23194.7 ± 50.02
Before Lunch152.4 ± 48.13163.4 ± 49.8
After Lunch158.0 ± 42.79183.8 ± 47.73
Before Dinner157.4 ± 49.34164.7 ± 40.60
After Dinner164.3 ± 44.84188.5 ± 43.93
Bedtime163.0 ± 42.66178.7 ± 44.50
SecondaryChange in Body Weight From Baseline to Week 24

Change in body weight from Baseline to Week 24

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · kg
Change in Body Weight From Baseline to Week 24
kgTI Inhalation Powder + OADsTechnosphere Powder
Change in Body Weight From Baseline to Week 240.49 ± 0.333-1.13 ± 0.347
Statistical analysis
  • TI Inhalation Powder + OADs vs Technosphere Powder · ANCOVA · p = <0.0001 · Mean difference (final values): 1.62 · 95% CI 0.90 to 2.34Model: Baseline Weight + Change in HbA1c at Week 24 + Region + OAD Stratum + Treatment

Adverse events

Collected over 24 Weeks. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
TI Inhalation Powder—5/177 (2.8%)108/177 (61%)
Technosphere Powder—9/176 (5.1%)82/176 (46.6%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventTI Inhalation PowderTechnosphere Powder
Myocardial InfarctionCardiac disorders2/1770/176
Angina PectorisCardiac disorders0/1771/176
Coronary Artery DiseaseCardiac disorders0/1771/176
CyanosisCardiac disorders0/1771/176
Skull MalformationCongenital, familial and genetic disorders0/1771/176
Humerus FractureInjury, poisoning and procedural complications0/1771/176
Heart Rate DecreasedInvestigations0/1771/176
Back PainMusculoskeletal and connective tissue disorders0/1771/176
Squamous Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1771/176
Ischemic StrokeNervous system disorders0/1771/176
Most frequent other events
Showing 10 of 13
Most frequent other events
EventTI Inhalation PowderTechnosphere Powder
CoughRespiratory, thoracic and mediastinal disorders42/17735/176
NasopharyngitisInfections and infestations15/1778/176
InfluenzaInfections and infestations10/1773/176
Upper Respiratory Tract InfectionInfections and infestations9/1775/176
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders8/1774/176
BronchitisInfections and infestations5/1777/176
HeadacheNervous system disorders7/1775/176
DiarrhoeaGastrointestinal disorders6/1773/176
Urinary Tract InfectionInfections and infestations6/1772/176
Respiratory Tract Infection ViralInfections and infestations2/1775/176

Baseline characteristics

Safety population

Age, Customized
Age, Customized(participants)TI Inhalation Powder + OADsTechnosphere PowderTotal
18-30 years101
31-49 years373370
50-64 years102110212
>=65 years373370
Sex: Female, Male
Sex: Female, Male(Participants)TI Inhalation Powder + OADsTechnosphere PowderTotal
Female95102197
Male8274156
Race (NIH/OMB)
Race (NIH/OMB)(Participants)TI Inhalation Powder + OADsTechnosphere PowderTotal
American Indian or Alaska Native112
Asian123
Native Hawaiian or Other Pacific Islander000
Black or African American211738
White151155306
More than one race000
Unknown or Not Reported314
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)TI Inhalation Powder + OADsTechnosphere PowderTotal
Hispanic or Latino434184
Not Hispanic or Latino134135269
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)TI Inhalation Powder + OADsTechnosphere PowderTotal
United States8887175
Brazil151429
Ukraine191938
Russian Federation5556111
Duration of Diabetes
Duration of Diabetes(years)TI Inhalation Powder + OADsTechnosphere PowderTotal
Mean9.7 (1.1 to 34.7)9.2 (1.0 to 28.8)9.5 (1.0 to 34.7)
Weight
Weight(kg)TI Inhalation Powder + OADsTechnosphere PowderTotal
Mean90.2 (54.0 to 142.3)90.8 (58.0 to 136.6)90.5 (54.0 to 142.3)
BMI
BMI(kg/m^2)TI Inhalation Powder + OADsTechnosphere PowderTotal
Mean31.8 (21.6 to 44.6)32.4 (21.1 to 44.4)32.1 (21.1 to 44.6)

3 further baseline measures are reported on the registry.

08

Study locations

76 sites
  • Anaheim, California 92807, United States
  • Huntington Beach, California 92648, United States
  • Laguna Hills, California 92653, United States
  • Long Beach, California 90806, United States
  • Los Angeles, California 90036, United States
  • Los Gatos, California 95032, United States
  • Tustin, California 92780, United States
  • West Hills, California 91307, United States
  • Hialeah, Florida 33012, United States
  • Hollywood, Florida 33021, United States
  • Miami, Florida 33156, United States
  • Miami, Florida 33173, United States
  • New Port Richey, Florida 34652, United States
  • North Miami Beach, Florida 33179, United States
  • Pembroke Pines, Florida 33026, United States
  • Pinellas Park, Florida 33781, United States
  • West Palm Beach, Florida 33401, United States
  • Atlanta, Georgia 30308, United States
  • Atlanta, Georgia 30318, United States
  • Dunwoody, Georgia 30338, United States
  • Lawrenceville, Georgia 30045, United States
  • Roswell, Georgia 30076, United States
  • Chicago, Illinois 60607, United States
  • Baton Rouge, Louisiana 70808, United States
  • Edina, Minnesota 55435, United States
  • Jefferson City, Missouri 65109, United States
  • St Peters, Missouri 63376, United States
  • St. Louis, Missouri 63110, United States
  • St. Louis, Missouri 63117, United States
  • Omaha, Nebraska 68114, United States
  • Omaha, Nebraska 68131, United States
  • Clifton, New Jersey 07012, United States
  • Hackensack, New Jersey 07601, United States
  • Paramus, New Jersey 07652, United States
  • Flushing, New York 11365, United States
  • New Hyde, New York 11042, United States
  • Greenville, North Carolina 27834, United States
  • Perrysburg, Ohio 43551, United States
  • Portland, Oregon 97239, United States
  • Greer, South Carolina 29651, United States
  • Memphis, Tennessee 38119, United States
  • Arlington, Texas 76014, United States
  • Dallas, Texas 75230, United States
  • Dallas, Texas 75246, United States
  • Houston, Texas 77095, United States
  • San Antonio, Texas 78229, United States
  • San Antonio, Texas 78249, United States
  • Magna, Utah 84044, United States
  • Renton, Washington 98057, United States
  • Wenatchee, Washington 98801, United States
  • Porto Alegre, 90035, Brazil
  • Sao Paulo, 01244, Brazil
  • Kemerovo, 650066, Russian Federation
  • Leningrad Region, Russian Federation
  • Moscow, 105120, Russian Federation
  • Moscow, 117036, Russian Federation
  • Moscow, 119435, Russian Federation
  • Moscow, 119991, Russian Federation
  • Moscow, 121374, Russian Federation
  • Moscow, 129128, Russian Federation
  • Moscow, 143420, Russian Federation
  • Petrozavodsk, 185019, Russian Federation
  • Smolensk, 214018, Russian Federation
  • St. Petersburg, 194044, Russian Federation
  • St. Petersburg, 194354, Russian Federation
  • St. Petersburg, 195257, Russian Federation
  • St. Petersburg, 196601, Russian Federation
  • St. Petersburg, 198013, Russian Federation
  • Yaroslavl, 150003, Russian Federation
  • Yaroslavl, 150023, Russian Federation
  • Kharkiv, UKR 61070, Ukraine
  • Kiev, UKR 04053, Ukraine
  • Kyiv, UKR 02175, Ukraine
  • Odesa, UKR 65039, Ukraine
  • Vinnytsya, UKR 21010, Ukraine
  • Kiev, 04114, Ukraine
09

References and documents

Publications

  • Rosenstock J, Franco D, Korpachev V, Shumel B, Ma Y, Baughman R, Amin N, McGill JB; Affinity 2 Study Group. Inhaled Technosphere Insulin Versus Inhaled Technosphere Placebo in Insulin-Naive Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetes Agents. Diabetes Care. 2015 Dec;38(12):2274-81. doi: 10.2337/dc15-0629. Epub 2015 Aug 7. PubMed 26253730 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2011, a primary completion of Jun 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year 4 months after primary completion. A results delay was requested in Aug 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2011
First posted
Oct 13, 2011
Start
Nov 2011
Primary completionActual
Jun 2013
CompletionActual
Jul 2013
Results delay requested
Aug 19, 2013
Results first posted
Oct 17, 2014
Last update
Oct 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01451398
Responsible party
Sponsor
First posted
Oct 13, 2011
Start date
Nov 2011
Primary completion
Jun 2013
Completion
Jul 2013
Results posted
Oct 17, 2014
Last update
Oct 17, 2014

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin, Regular, Human

Start the discussion